French Interventional Radiology Centers' Uptake of Transradial Approach and Outpatient HCC Intra-Arterial Treatments.
Accountable care organizations
Hepatocellular carcinoma
Outpatient
Transarterial chemoembolization
Transarterial radioembolization
Transradial approach
Journal
Cardiovascular and interventional radiology
ISSN: 1432-086X
Titre abrégé: Cardiovasc Intervent Radiol
Pays: United States
ID NLM: 8003538
Informations de publication
Date de publication:
06 Nov 2023
06 Nov 2023
Historique:
received:
30
05
2023
accepted:
01
10
2023
medline:
6
11
2023
pubmed:
6
11
2023
entrez:
6
11
2023
Statut:
aheadofprint
Résumé
This study aims to investigate the uptake of transradial approach (TRA) and outpatient setting for transarterial chemoembolization (TACE) and transarterial radioembolization (TARE) in the treatment of hepatocellular carcinoma (HCC) among French interventional radiology centers. This cross-sectional study was based on a 34-question survey assessing center activity, radial access, and outpatient care. The survey was developed by a working group, tested by two external experts, and distributed to active members of two French radiological societies via a web-based self-reporting questionnaire in March 2022. The survey remained open for eight weeks, with two reminder emails sent to non-responders. Only one answer per center was considered. Of the 44 responding centers, 39% (17/44) performed TRA for TACE and/or TARE, with post-procedure patient comfort as main motivation. Among the 27 centers not performing TRA, 33% (9/27) reported a lack of technical experience, but all 27 intended to adopt TRA within two years. Only six centers performed TACE or TARE in an outpatient setting. Reasons limiting its implementation included TACE for HCC not being a suitable intervention (61%, 27/44) and organizational barriers (41%, 18/44). Among centers not performing outpatient TACE or TARE, 34% (13/38) said "No," 34% (13/38) said "Maybe," and 32% (12/38) said "Yes" when asked about adopting it within two years. French interventional radiologists have low TRA uptake for HCC treatment, but TRA adoption potential exists. Respondents were uncertain about performing TACE or TARE in an outpatient setting within a 2-year horizon.
Identifiants
pubmed: 37930400
doi: 10.1007/s00270-023-03578-9
pii: 10.1007/s00270-023-03578-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).
Références
Fritsche MR, Watchmaker JM, Lipnik AJ, et al. Outpatient Transarterial chemoembolization of hepatocellular carcinoma: review of a same-day discharge strategy. J Vasc Interv Radiol. 2018;29(4):550–5. https://doi.org/10.1016/j.jvir.2017.11.018 .
doi: 10.1016/j.jvir.2017.11.018
pubmed: 29478795
Mitchell JW, O’Connell WG, Kisza P, et al. Safety and feasibility of outpatient transcatheter hepatic arterial embolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2009;20(2):203–8. https://doi.org/10.1016/j.jvir.2008.10.027 .
doi: 10.1016/j.jvir.2008.10.027
pubmed: 19097805
Nasser F, Cavalcante RN, Galastri FL, et al. Safety and feasibility of same-day discharge of patients with hepatocellular carcinoma treated with transarterial chemoembolization with drug-eluting beads in a liver transplantation program. J Vasc Interv Radiol. 2014;25(7):1012–7. https://doi.org/10.1016/j.jvir.2014.02.025 .
doi: 10.1016/j.jvir.2014.02.025
pubmed: 24704346
Prajapati HJ, Rafi S, El-Rayes BF, Kauh JS, Kooby DA, Kim HS. Safety and feasibility of same-day discharge of patients with unresectable hepatocellular carcinoma treated with doxorubicin drug-eluting bead transcatheter chemoembolization. J Vasc Interv Radiol. 2012;23(10):1286–93. https://doi.org/10.1016/j.jvir.2012.07.003 .
doi: 10.1016/j.jvir.2012.07.003
pubmed: 22999748
Iezzi R, Pompili M, Posa A, et al. Transradial versus transfemoral access for hepatic chemoembolization: intrapatient prospective single-center study. J Vasc Interv Radiol. 2017;28(9):1234–9. https://doi.org/10.1016/j.jvir.2017.06.022 .
doi: 10.1016/j.jvir.2017.06.022
pubmed: 28757286
Yamada R, Bracewell S, Bassaco B, et al. Transradial versus transfemoral arterial access in liver cancer embolization: randomized trial to assess patient satisfaction. J Vasc Interv Radiol. 2018;29(1):38–43. https://doi.org/10.1016/j.jvir.2017.08.024PMID-29150395 .
doi: 10.1016/j.jvir.2017.08.024PMID-29150395
pubmed: 29150395
Liu LB, Cedillo MA, Bishay V, et al. Patient experience and preference in transradial versus transfemoral access during transarterial radioembolization: a randomized single-center trial. J Vasc Interv Radiol. 2019;30(3):414–20. https://doi.org/10.1016/j.jvir.2018.10.005 .
doi: 10.1016/j.jvir.2018.10.005
pubmed: 30819485
Brueck M, Bandorski D, Kramer W, Wieczorek M, Höltgen R, Tillmanns H. A randomized comparison of transradial versus transfemoral approach for coronary angiography and angioplasty. Jacc Cardiovasc Intervent. 2009;2(11):1047–54. https://doi.org/10.1016/j.jcin.2009.07.016PMID-19926042 .
doi: 10.1016/j.jcin.2009.07.016PMID-19926042
Karrowni W, Vyas A, Giacomino B, et al. Radial versus femoral access for primary percutaneous interventions in ST-segment elevation myocardial infarction patients a meta-analysis of randomized controlled trials. Jacc Cardiovasc Intervent. 2013;6(8):814–23. https://doi.org/10.1016/j.jcin.2013.04.010PMID-23968700 .
doi: 10.1016/j.jcin.2013.04.010PMID-23968700
Agostoni P, Biondi-Zoccai GGL, Benedictis MLD, et al. Radial versus femoral approach for percutaneous coronary diagnostic and interventional procedures systematic overview and meta-analysis of randomized trials. J Am Coll Cardiol. 2004;44(2):349–56. https://doi.org/10.1016/j.jacc.2004.04.034PMID-15261930 .
doi: 10.1016/j.jacc.2004.04.034PMID-15261930
pubmed: 15261930
Posham R, Biederman DM, Patel RS, et al. Transradial approach for noncoronary interventions: a single-center review of safety and Feasibility in the first 1,500 cases. J Vasc Interv Radiol. 2016;27(2):159–66. https://doi.org/10.1016/j.jvir.2015.10.026PMID-26706186 .
doi: 10.1016/j.jvir.2015.10.026PMID-26706186
pubmed: 26706186
Jolly SS, Yusuf S, Cairns J, et al. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet. 2011;377(9775):1409–20. https://doi.org/10.1016/s0140-6736(11)60404-2PMID-21470671 .
doi: 10.1016/s0140-6736(11)60404-2PMID-21470671
pubmed: 21470671
Mamas MA, Ratib K, Routledge H, et al. Influence of access site selection on PCI-related adverse events in patients with STEMI: meta-analysis of randomised controlled trials. Heart. 2012;98(4):303. https://doi.org/10.1136/heartjnl-2011-300558PMID-22147900 .
doi: 10.1136/heartjnl-2011-300558PMID-22147900
pubmed: 22147900
Brasselet C, Tassan S, Nazeyrollas P, Hamon M, Metz D. Randomised comparison of femoral versus radial approach for percutaneous coronary intervention using abciximab in acute myocardial infarction: results of the FARMI trial. Heart. 2007;93(12):1556. https://doi.org/10.1136/hrt.2007.117309PMID-17639099 .
doi: 10.1136/hrt.2007.117309PMID-17639099
pubmed: 17639099
pmcid: 2095748
Goldberg SL, Renslo R, Sinow R, French WJ. Learning curve in the use of the radial artery as vascular access in the performance of percutaneous transluminal coronary angioplasty. Catheter Cardio Diag. 1998;44(2):147–52. https://doi.org/10.1002/(sici)1097-0304(199806)44:2%3c147::aid-ccd5%3e3.0.co;2-6PMID-9637436 .
doi: 10.1002/(sici)1097-0304(199806)44:2<147::aid-ccd5>3.0.co;2-6PMID-9637436
Gayed A, Yamada R, Bhatia S, et al. Society of interventional radiology quality improvement standards on radial artery access. J Vasc Interv Radiol. 2021;32(5):761.e761-761.e721. https://doi.org/10.1016/j.jvir.2020.12.013PMID-33933252 .
doi: 10.1016/j.jvir.2020.12.013PMID-33933252
Dehghani P, Mohammad A, Bajaj R, et al. Mechanism and predictors of failed transradial approach for percutaneous coronary interventions. Jacc Cardiovasc Intervent. 2009;2(11):1057–64. https://doi.org/10.1016/j.jcin.2009.07.014PMID-19926044 .
doi: 10.1016/j.jcin.2009.07.014PMID-19926044
Valsecchi O, Vassileva A, Musumeci G, et al. Failure of transradial approach during coronary interventions: anatomic considerations. Catheter Cardio Inte. 2006;67(6):870–8. https://doi.org/10.1002/ccd.20732PMID-16649233 .
doi: 10.1002/ccd.20732PMID-16649233
Bertrand OF, Rao SV, Pancholy S, et al. Transradial approach for coronary angiography and interventions results of the first international transradial practice survey. Jacc Cardiovasc Intervent. 2010;3(10):1022–31. https://doi.org/10.1016/j.jcin.2010.07.013PMID-20965460 .
doi: 10.1016/j.jcin.2010.07.013PMID-20965460
Iezzi R, Posa A, Bilhim T, Guimaraes M. Most common misconceptions about transradial approach in interventional radiology: results from an international survey. Diagnostic Intervent Radiol. 2021;27(5):649–53.
doi: 10.5152/dir.2021.20256
Hadjivassiliou A, Cardarelli-Leite L, Jalal S, et al. Left distal transradial access (ldTRA): a comparative assessment of conventional and distal radial artery size. Cardiovasc Intervent Radiol. 2020;43(6):850–7. https://doi.org/10.1007/s00270-020-02485-7 .
doi: 10.1007/s00270-020-02485-7
pubmed: 32342166
Hsieh M-Y, Lin L, Tsai K-C, Wu C-C. Radial artery approach to salvage nonmaturing radiocephalic arteriovenous fistulas. Cardiovasc Intervent Radiol. 2013;36(4):957–63. https://doi.org/10.1007/s00270-012-0533-7 .
doi: 10.1007/s00270-012-0533-7
pubmed: 23238850
Yip H-K, Youssef AA, Chang W-N, et al. Feasibility and safety of transradial arterial approach for simultaneous right and left vertebral artery angiographic studies and stenting. Cardiovasc Intervent Radiol. 2007;30(5):840–6. https://doi.org/10.1007/s00270-007-9051-4 .
doi: 10.1007/s00270-007-9051-4
pubmed: 17587084
Fohlen A, Tasu JP, Kobeiter H, Bartoli JM, Pelage JP, Guiu B. Transarterial chemoembolization (TACE) in the management of hepatocellular carcinoma: results of a French national survey on current practices. Diagn Interv Imaging. 2018;99(9):527–35. https://doi.org/10.1016/j.diii.2018.03.003 .
doi: 10.1016/j.diii.2018.03.003
pubmed: 29609903
Steele JR, Wallace MJ, Hovsepian DM, et al. Guidelines for establishing a quality improvement program in interventional radiology. J Vasc Interv Radiol. 2010;21(5):617–25.
doi: 10.1016/j.jvir.2010.01.010
pubmed: 20299244
Zuckerman RB, Sheingold SH, Orav EJ, Ruhter J, Epstein AM. Readmissions, observation, and the hospital readmissions reduction program. N Engl J Med. 2016;374(16):1543–51.
doi: 10.1056/NEJMsa1513024
pubmed: 26910198
Hund HC, Frantz SK, Wu H, et al. Six-year evaluation of same-day discharge following conventional transarterial chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol. 2023;34(3):378–85. https://doi.org/10.1016/j.jvir.2022.11.029 .
doi: 10.1016/j.jvir.2022.11.029
pubmed: 36481322
de Baere T, Ronot M, Chung JW, et al. Initiative on superselective conventional transarterial chemoembolization results (INSPIRE). Cardiovasc Intervent Radiol. 2022;45(10):1430–40.
doi: 10.1007/s00270-022-03233-9
pubmed: 35978174
pmcid: 9499883
Vanderbecq Q, Grégory J, Dana J, et al. Improving pain control during transarterial chemoembolization for hepatocellular carcinoma performed under local anesthesia with multimodal analgesia. Diagn Interv Imaging. 2023;104(3):123–32. https://doi.org/10.1016/j.diii.2022.10.013 .
doi: 10.1016/j.diii.2022.10.013
pubmed: 36805801
Delicque J, Hermida M, Piron L, et al. Intra arterial treatment of hepatocellular carcinoma: comparison of MELD score variations between radio-embolization and chemo-embolization. Diagn Interv Imaging. 2019;100(11):689–97. https://doi.org/10.1016/j.diii.2019.05.006 .
doi: 10.1016/j.diii.2019.05.006
pubmed: 31281074
Wu SE, Charles HW, Park JS, Goldenberg AS, Deipolyi AR. Obesity conveys poor outcome in patients with hepatocellular carcinoma treated by transarterial chemoembolization. Diagn Interv Imaging. 2017;98(1):37–42. https://doi.org/10.1016/j.diii.2016.06.002 .
doi: 10.1016/j.diii.2016.06.002
pubmed: 27372418
Gregory J, Tselikas L, Allimant C, et al. Defining textbook outcome for selective internal radiation therapy of hepatocellular carcinoma: an international expert study. Eur J Nucl Med Mol Imaging. 2023;50(3):921–8. https://doi.org/10.1007/s00259-022-06002-5 .
doi: 10.1007/s00259-022-06002-5
pubmed: 36282299
Maleux G, Albrecht T, Arnold D, et al. Predictive factors for adverse event outcomes after transarterial radioembolization with yttrium-90 resin microspheres in europe: results from the prospective observational CIRT study. Cardiovasc Intervent Radiol. 2023. https://doi.org/10.1007/s00270-023-03391-4 .
doi: 10.1007/s00270-023-03391-4
pubmed: 37884799
pmcid: 10322946
Gabr A, Kallini JR, Gates VL, et al. Same-day 90Y radioembolization: implementing a new treatment paradigm. Eur J Nucl Med Mol Imaging. 2016;43(13):2353–9. https://doi.org/10.1007/s00259-016-3438-xPMID-27315059 .
doi: 10.1007/s00259-016-3438-xPMID-27315059
pubmed: 27315059
Li MD, Chu KF, DePietro A, et al. Same-day yttrium-90 radioembolization: feasibility with resin microspheres. J Vasc Interv Radiol. 2019;30(3):314–9.
doi: 10.1016/j.jvir.2018.10.016
pubmed: 30819470
Lublóy Á. Factors affecting the uptake of new medicines: a systematic literature review. BMC Health Serv Res. 2014;14(1):469. https://doi.org/10.1186/1472-6963-14-469 .
doi: 10.1186/1472-6963-14-469
pubmed: 25331607
pmcid: 4283087